within Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J05A_DirectActingAntivirals.J05AB01_Aciclovir;

model Aciclovir
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_1C_enteral(
    weight = 70,
    F = 0.2,
    Cl = 4.583333333333332e-06,
    adminDuration = 600,
    adminMass = 400 / 1000000,
    adminCount = 1,
    Vd = 0.00065,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.016666666666666666,
    Tlag = 0);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Aciclovir</td></tr><tr><td>ATC code:</td><td>J05AB01</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>1</td></tr>
    <tr><td>dosage:</td><td>400</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>0.65</td><td>L</td></tr>
    <tr><td>clearance:</td><td>275</td><td>mL/min</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Aciclovir (also known as acyclovir) is an antiviral drug used primarily for the treatment of infections caused by herpes simplex virus (HSV) and varicella-zoster virus (VZV), such as genital herpes, cold sores, shingles, and chickenpox. It inhibits viral DNA polymerase and is approved for clinical use worldwide.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in healthy adult volunteers after oral administration.</p><h4>References</h4><ol><li><p>O&#x27;Brien, JJ, &amp; Campoli-Richards, DM (1989). Acyclovir. An updated review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy. <i>Drugs</i> 37(3) 233–309. DOI:<a href=\"https://doi.org/10.2165/00003495-198937030-00002\">10.2165/00003495-198937030-00002</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/2653790/\">https://pubmed.ncbi.nlm.nih.gov/2653790</a></p></li><li><p>Patel, R (1997). Valaciclovir: development, clinical utility and potential. <i>Expert opinion on investigational drugs</i> 6(2) 173–189. DOI:<a href=\"https://doi.org/10.1517/13543784.6.2.173\">10.1517/13543784.6.2.173</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/15989601/\">https://pubmed.ncbi.nlm.nih.gov/15989601</a></p></li><li><p>Noble, S, &amp; Faulds, D (1998). Ganciclovir. An update of its use in the prevention of cytomegalovirus infection and disease in transplant recipients. <i>Drugs</i> 56(1) 115–146. DOI:<a href=\"https://doi.org/10.2165/00003495-199856010-00012\">10.2165/00003495-199856010-00012</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/9664203/\">https://pubmed.ncbi.nlm.nih.gov/9664203</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.J.J05AB01 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Aciclovir;
